CA3043640A1 - Human plasma-like medium - Google Patents
Human plasma-like medium Download PDFInfo
- Publication number
- CA3043640A1 CA3043640A1 CA3043640A CA3043640A CA3043640A1 CA 3043640 A1 CA3043640 A1 CA 3043640A1 CA 3043640 A CA3043640 A CA 3043640A CA 3043640 A CA3043640 A CA 3043640A CA 3043640 A1 CA3043640 A1 CA 3043640A1
- Authority
- CA
- Canada
- Prior art keywords
- culture medium
- cells
- concentration
- assay
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/32—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of substances in solution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421074P | 2016-11-11 | 2016-11-11 | |
| US62/421,074 | 2016-11-11 | ||
| PCT/US2017/061377 WO2018089928A1 (en) | 2016-11-11 | 2017-11-13 | Human plasma-like medium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3043640A1 true CA3043640A1 (en) | 2018-05-17 |
Family
ID=62110050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3043640A Pending CA3043640A1 (en) | 2016-11-11 | 2017-11-13 | Human plasma-like medium |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11453858B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3538151B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7406990B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110121359A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043640A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018089928A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089928A1 (en) | 2016-11-11 | 2018-05-17 | Whitehead Institute For Biomedical Research | Human plasma-like medium |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| US20220003750A1 (en) * | 2018-12-01 | 2022-01-06 | The Regents Of The University Of Colorado, A Body Corporate | Functional screen for small molecule and monoclonal antibody drug sensitivity in multiple myeloma patients |
| WO2020264072A1 (en) * | 2019-06-25 | 2020-12-30 | Semma Therapeutics, Inc. | Enhanced differentiation of beta cells |
| US12297451B1 (en) * | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN113005082B (zh) * | 2019-12-20 | 2023-08-18 | 苏州依科赛生物科技股份有限公司 | 一种t细胞无血清培养基及其应用 |
| CN111334472A (zh) * | 2020-03-27 | 2020-06-26 | 郑州鲲鹏健康科技有限公司 | Pbmc体外3d胶原蛋白水凝胶培养基及其制备方法 |
| CN112029718B (zh) * | 2020-09-17 | 2023-04-07 | 深圳博雅感知药业有限公司 | 无血清驯化培养间充质干细胞的方法和所用的培养基 |
| CN113230391A (zh) * | 2021-05-13 | 2021-08-10 | 杭州医学院 | 尿酸酶在制备抗肿瘤药物增敏剂中的应用 |
| CN114317446B (zh) * | 2021-12-30 | 2023-12-05 | 广州康盛生物科技股份有限公司 | 一种无血清培养基用添加剂及其应用 |
| CN114457149A (zh) * | 2022-01-05 | 2022-05-10 | 中南大学湘雅二医院 | 筛选别嘌醇耐受的基因甲基化标志物的应用及检测试剂 |
| CN114634910B (zh) * | 2022-03-09 | 2024-03-08 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种胃癌细胞的培养基及其培养方法 |
| CN116515754B (zh) * | 2023-03-17 | 2024-01-30 | 创芯国际生物科技(广州)有限公司 | 一种脂肪肉瘤类器官、培养基及培养方法 |
| CN116751737B (zh) * | 2023-08-16 | 2023-11-14 | 上海科新生物技术股份有限公司 | 无血清无蛋白培养基和制备方法及其应用 |
| IL328729A (en) | 2023-12-01 | 2026-07-01 | Sigilon Therapeutics Inc | Methods for producing stem cell-derived islet-like cells, as well as populations and compositions comprising them |
| CN118240744B (zh) * | 2024-03-06 | 2024-11-26 | 上海迈邦生物科技有限公司 | 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法 |
| CN118374562B (zh) * | 2024-06-26 | 2024-09-03 | 山东润德生物科技有限公司 | 一种用于制备n-乙酰氨基葡萄糖的发酵培养基 |
| CN119286765A (zh) * | 2024-12-10 | 2025-01-10 | 山东伯桢生物科技有限公司 | 类器官基础培养基及维持和促进类器官生长的方法 |
| WO2026142011A1 (ko) * | 2024-12-27 | 2026-07-02 | 주식회사 스웬 | 생체 샘플 기반 추모 물품 제작 장치 및 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62278980A (ja) * | 1986-05-29 | 1987-12-03 | Morinaga & Co Ltd | 細胞増殖因子 |
| DE544887T1 (de) | 1991-06-17 | 1994-02-03 | Life Technologies Inc | Technik zur konzentration von kulturmedien. |
| ATE205850T1 (de) * | 1991-07-05 | 2001-10-15 | Pro Neuron Inc | Behandlung der toxischen wirkung von chemotherapeutischen und antiviralen wirkstoffen mit acylierten pyrimidinnukleosiden |
| DK0996636T3 (da) | 1997-07-23 | 2005-04-25 | Univ Leiden | HA-1-antigenet |
| GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
| US20070004036A1 (en) | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for keratinocyte culture |
| WO2007030795A2 (en) * | 2005-09-09 | 2007-03-15 | Cytokinetics, Inc. | Cellular phenotype |
| US8849577B2 (en) * | 2006-09-15 | 2014-09-30 | Metabolon, Inc. | Methods of identifying biochemical pathways |
| JP2008109866A (ja) | 2006-10-30 | 2008-05-15 | Jms Co Ltd | 培地添加剤、この培地添加剤を含む培地、及びこの培地を用いた細胞の培養方法 |
| US20110244502A1 (en) * | 2007-08-10 | 2011-10-06 | Whitehead Institute For Biomedical Research | Hormone responsive tissue culture system and uses thereof |
| BRPI0819847B1 (pt) | 2007-11-27 | 2022-01-11 | Ardea Biosciences, Inc | Compostos e composições |
| US20100160351A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| TWI499412B (zh) | 2010-06-16 | 2015-09-11 | 亞德生化公司 | 苯基硫乙酸酯組合物及其使用方法 |
| JP5990106B2 (ja) | 2011-01-28 | 2016-09-07 | 佐藤製薬株式会社 | 縮環化合物 |
| ES2664219T3 (es) | 2011-01-28 | 2018-04-18 | Immunic Ag | Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria |
| WO2012125533A1 (en) | 2011-03-14 | 2012-09-20 | Wellstat Therapeutics Corporation | 3-benzyloxyphenyloxoacetic acid compounds for reducing uric acid |
| WO2012141571A1 (en) | 2011-04-11 | 2012-10-18 | M Abdullah Jaffar Ali Bin | Protein-free culture media products |
| US20120276215A1 (en) * | 2011-04-26 | 2012-11-01 | Riordan Neil H | Therapeutic Conditioned Media |
| US9034584B2 (en) | 2011-07-29 | 2015-05-19 | Cellular Dynamics International, Inc. | Metabolic maturation in stem cell-derived tissue cells |
| WO2014017643A1 (ja) | 2012-07-27 | 2014-01-30 | 佐藤製薬株式会社 | ジフルオロメチレン化合物 |
| CN102994441A (zh) * | 2012-09-19 | 2013-03-27 | 上海瀚康生物医药科技有限公司 | 一种细胞培养基及其制备方法和用途 |
| NO2760138T3 (cg-RX-API-DMAC7.html) | 2012-10-01 | 2018-08-04 | ||
| US20190100725A1 (en) * | 2016-03-18 | 2019-04-04 | Institute Of Biophysics, Chinese Academy Of Sciences | Cell culture medium and culture medium supplement |
| WO2018089928A1 (en) | 2016-11-11 | 2018-05-17 | Whitehead Institute For Biomedical Research | Human plasma-like medium |
-
2017
- 2017-11-13 WO PCT/US2017/061377 patent/WO2018089928A1/en not_active Ceased
- 2017-11-13 EP EP17869135.8A patent/EP3538151B1/en active Active
- 2017-11-13 US US16/348,402 patent/US11453858B2/en active Active
- 2017-11-13 CA CA3043640A patent/CA3043640A1/en active Pending
- 2017-11-13 CN CN201780081328.2A patent/CN110121359A/zh active Pending
- 2017-11-13 JP JP2019524430A patent/JP7406990B2/ja active Active
-
2022
- 2022-08-04 US US17/881,200 patent/US20230051644A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3538151B1 (en) | 2024-06-26 |
| WO2018089928A1 (en) | 2018-05-17 |
| US20190352598A1 (en) | 2019-11-21 |
| US11453858B2 (en) | 2022-09-27 |
| EP3538151A4 (en) | 2020-06-10 |
| US20230051644A1 (en) | 2023-02-16 |
| CN110121359A (zh) | 2019-08-13 |
| JP7406990B2 (ja) | 2023-12-28 |
| EP3538151A1 (en) | 2019-09-18 |
| JP2020501522A (ja) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230051644A1 (en) | Human plasma-like medium | |
| Cantor et al. | Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase | |
| Koundinya et al. | Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers | |
| Groelly et al. | Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours | |
| Pluskal et al. | Specific biomarkers for stochastic division patterns and starvation‐induced quiescence under limited glucose levels in fission yeast | |
| Valvezan et al. | IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex | |
| EP1047938A2 (en) | Identification of substances that modify cellular secretory function | |
| TW201726169A (zh) | Pd-1訊息抑制劑之併用療法 | |
| JP2020501522A5 (cg-RX-API-DMAC7.html) | ||
| Bose et al. | Absence of activation of DNA repair genes and excellent efficacy of phosphaplatins against human ovarian cancers: implications to treat resistant cancers | |
| Talvas et al. | Regulation of protein synthesis by leucine starvation involves distinct mechanisms in mouse C2C12 myoblasts and myotubes | |
| Husseiny et al. | The role of B12 deficiency and methionine synthase in methionine-dependent cancer cells | |
| TW200804350A (en) | Aryl-substituted quinazolones, and uses thereof | |
| Bornkamm et al. | Burkitt’s Lymphoma and Early B Cell Transformation as Paradigms of How Epstein-Barr Virus Overcomes Apoptosis and Ferroptosis | |
| Reichel et al. | Fluo‐cAMP is transported by multidrug resistance‐associated protein isoform 4 in rat choroid plexus | |
| El Husseiny et al. | Methionine dependence in cancer cells due to lack of B12-dependent methionine synthase activity | |
| El Husseiny et al. | The role of B | |
| Apostolova | The RING domain of Nse1: roles in Smc5/6 complex stability and genome integrity in human cells | |
| Villarreal | Exploring novel roles of metabolic enzymes MTHFD2 and PFKFB3 in cancer genome stability and their potential as anticancer therapeutic targets | |
| Perret et al. | Phosphoserine aminotransferase SerC is a central metabolic checkpoint and druggable vulnerability in Mycobacterium tuberculosis | |
| Real | Small Molecule Interactions Directed to the Scaffold Kinase Suppressor of Ras Modulate MAPK Signaling in Cancer | |
| Fantozzi | Influence of centrosome amplification on the response to chemotherapy in epithelial ovarian cancer | |
| Kraus | The role of mitochondrial complex II in cancer cell biology | |
| Gibbs | The In Vivo Development of Folate Receptor-Targeted Thymidylate Synthase Inhibitors | |
| HAMRELL et al. | Transient induction of phenotypic resistance in human lymphoblastoid cells following sequential use of two antifolates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241108 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241108 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250723 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251126 |